Stoke Therapeutics, INC 10-Q quarterly reports

Stoke Therapeutics reported a net loss of $61.6 million for Q2 2026, with revenue down significantly year-over-year, while advancing its zorevunersen and STK-002 programs.

Stoke Therapeutics reported a significant revenue increase driven by its Biogen collaboration and positive clinical progress for zorevunersen in Dravet syndrome, extending its cash runway to mid-2028.

Stoke Therapeutics reported a significant net income for the first half of 2025, driven by a major collaboration with Biogen, while advancing its clinical programs for Dravet syndrome and ADOA.

Stoke Therapeutics' Q1 2025 results showcase a significant revenue surge due to a new collaboration with Biogen, offsetting previous operating losses.

Stoke Therapeutics' Q3 2024 results show increased revenue from the Acadia collaboration, but continued net losses as the company advances its clinical programs.

Stoke Therapeutics reports a net loss of $25.7 million for the second quarter of 2024, alongside a revenue increase driven by its collaboration with Acadia Pharmaceuticals.

Stoke Therapeutics announced its first quarter 2024 financial results, highlighting progress in its clinical programs for Dravet syndrome and autosomal dominant optic atrophy.